Delenex Therapeutics makes two senior appointments

Eric de La Fortelle joins as ceo and Jakob Schlapbach as cfo

Swiss biotechnology firm Delenex Therapeutics has appointed Eric de La Fortelle as chief executive and Jakob Schlapbach as chief finance officer.

La Fortelle was previously global head of external research and technologies at F. Hoffmann-La Roche and more recently global head, emerging technologies. His scientific work contributed to the field of protein structure determination and he was the initial lead author of the SHARP software, which contributed to the resolution of more than 1,000 protein structures by X-ray crystallography.

Schlapbach joined Delenex last December 2010 as cfo. He brings more than 30 years of banking and industrial financing experience to the company. He was cfo of Cytos Biotechnology for more than 10 years until mid-2010 and held the same position at Ascom group between 1994 and 2000.


Thomas Hecht, chairman of Delenex, said: ‘We are pleased and proud to have attracted two managers of such a high calibre to Delenex.’

Delenex Therapeutics AG is developing therapeutic PENTRA antibody fragments targeting serious medical diseases with high unmet need.

Delenex is a spin-off from ESBATech before its acquisition by Alcon in September 2009 and operates out of laboratories and offices in Zürich-Schlieren.

You may also like

Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs
Research & Development

OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial

OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Regulatory

Johnson & Johnson files FDA application for IMAAVY in wAIHA

Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Research & Development

Almirall advances etherna’s mRNA/LNP therapy LAD116 into IND-enabling studies

Almirall has selected LAD116, developed using etherna's intratumoral mRNA/LNP platform, for IND-enabling studies in non-melanoma skin cancer, marking a key milestone toward GMP manufacturing and Phase I clinical trials
Research & Development

SPARK THE MIDLANDS backs Aston University anti-cancer bone paste collaboration

A collaboration between Aston University and Royal Orthopaedic Hospital NHS Foundation Trust has secured support from SPARK THE MIDLANDS to advance a minimally invasive gallium-doped injectable paste for treating primary and metastatic bone cancer
Subscribe now